Obesity & Cardiometabolic Health

Excess weight, especially abdominal (visceral) fat, adds mechanical strain to the heart. It also drives the biological processes behind heart disease: insulin resistance, chronic low-grade inflammation, and abnormal cholesterol patterns all become more common as visceral fat increases. Over time, this raises the risk of coronary artery disease, heart failure (including HFpEF, heart failure with preserved ejection fraction), and atrial fibrillation.

A cardiometabolic evaluation goes beyond weight and BMI. It typically considers:

This assessment shapes the treatment plan, which differs from patient to patient.

• Waist circumference / abdominal adiposity
• Blood pressure
• Lipid profile (cholesterol and triglycerides)
• Blood sugar / insulin resistance markers
• Existing cardiac risk factors or conditions
• Sleep-related cardiovascular risk (e.g. sleep apnea), where relevant

Cardiologist Consultation

Obesity, high blood pressure, high cholesterol, and diabetes frequently occur together and compound each other's cardiovascular impact. Managing obesity often improves all three, though each is also assessed and treated in its own right.

Hypertension · High Cholesterol · Diabetes & Heart Disease

Sustained cardiometabolic risk from obesity contributes directly to coronary artery disease over time. Separately, it contributes to heart failure, including HFpEF, a form increasingly linked to obesity and metabolic risk rather than to blocked arteries alone.

Coronary Artery Disease · Heart Failure

Sustainable dietary change and regular physical activity remain the foundation of cardiometabolic risk reduction, regardless of whether medical therapy is also used. The goal is a pattern that can be maintained long-term.

GLP-1 receptor agonists: semaglutide and tirzepatide. These are prescription medications (tirzepatide is marketed in India as Mounjaro, among other brands) that work on appetite and metabolic regulation, and are used for weight management as part of a broader cardiometabolic treatment plan, not as a standalone solution.

Cardiovascular evidence. This class of medication has been studied specifically for cardiovascular outcomes in patients with elevated cardiometabolic risk, in addition to their effect on weight. That is part of why they are considered here through a cardiology lens rather than purely for weight loss. How that evidence applies to your situation is something Dr. Kulin Sheth goes through with you in consultation.

Patient selection. Suitability depends on an individual's full cardiometabolic risk profile, other health conditions, and treatment goals. It's never applied as a default option for anyone wanting to lose weight.

Precautions. As with any prescription medication, there are situations where these drugs require caution or aren't appropriate. That is evaluated individually, based on personal and family medical history.

Common adverse effects. Gastrointestinal symptoms (such as nausea or digestive changes) are the most commonly reported effects, particularly when starting treatment. Any side effects should be raised with your doctor.

Long-term treatment considerations. These medications are generally intended for sustained use as part of ongoing management, and stopping treatment can be associated with weight regain. This is an important factor in long-term planning, and it belongs in the treatment decision from the start.

This page is intentionally general and educational. It does not provide dosing, prescribing guidance, or a personal treatment recommendation. Those decisions are made directly with Dr. Kulin, based on individual assessment.

The aim of cardiometabolic management is reducing cardiovascular risk and improving long-term heart health.